Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Oab Article
This is a selection made from among articles on Drug Treatment Oab. For a permanent link to this article, or to bookmark it for future reading, click here.
from:
Drug - Alcohol Rehab Program - The Addiction Theory Of Alcoholism
By Angel CH
Researchers, medical practitioners and addiction experts have technically defined addiction as:
"Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving."
In recent times, many experts in the field of addition have taken what can best be described as an addiction approach to alcoholism treatment. As a result, a great number of drug alcohol rehab program options are now available to people the world over.
For example, there are a growing number of highly regarded inpatient facilities that have established drug alcohol rehab program options for people suffering from alcoholism. These facilities undertake a drug alcohol rehab program in the same way that they address issues pertaining to other types of addiction and addictive behavior. These inpatient drug alcohol rehab program options include such treatments as:
* detox
* group therapy
* one on one therapy
* education
* relapse prevention planning
You also need to keep in mind that when it comes to a drug alcohol rehab program, many people actually have multiple addictions. For example, it is common for a person who is addicted to some sort of narcotic drug to also be addicted to alcohol. The patient with multiple addictions is become more commonplace all of the time. Therefore, there are many drug alcohol rehab program options that have been created to deal with and work to resolve multiple addictions in a patient.
Finally, when considering drug alcohol rehab program treatment options, a person will want to look at the one on one counseling option. For many individuals, one on one counseling proves to be an effective way of addressing alcoholism as well as other addictions. It proves to be a good tool on the road to sobriety and recovery.
You are about to know what alcoholic must know about drug alcohol rehab program. Angel CH is an expert and has been writing and researching about alcoholism facts daily. Discover the truth by visiting http://www.alcoholism-detox.com, a popular website that offers valuable alternative alcoholism treatment tips.
Article Source: http://EzineArticles.com/?expert=Angel_CH
http://EzineArticles.com/?Drug---Alcohol-Rehab-Program---The-Addiction-Theory-Of-Alcoholism&id=629977
Drug Treatment Oab Specific links
Drug Treatment Oab News
Flexible-dose antimuscarinic decreases nocturnal urgency episodes - ModernMedicine
Flexible-dose antimuscarinic decreases nocturnal urgency episodes ModernMedicine Fesoterodine treatment was initiated at 4 mg, once daily and could be increased to 8 mg at the 4-week visit if needed. The fesoterodine and control groups were similar in their baseline demographics and OAB symptoms. Nearly all nocturic micturitions ... |
NICE Rec for Allergan's Botox - Zacks.com
NICE Rec for Allergan's Botox Zacks.com Botox is already approved by the US Food and Drug Administration (FDA) for the treatment of chronic migraine headache in adults. Last year in August, Botox received FDA approval for the treatment of neurogenic overactive bladder (OAB). |
Antares Pharma Reports First Quarter 2012 Financial and Operating Results - MarketWatch (press release)
Antares Pharma Reports First Quarter 2012 Financial and Operating Results MarketWatch (press release) Announced, along with our partner Watson, the launch of Gelnique 3%(TM) for the treatment of overactive bladder (OAB). Watson will detail Gelnique 3% to physicians with their well-established commercial team focused on urology. |
Antares Pharma Reports First Quarter 2012 Financial and Operating Results - EON: Enhanced Online News (press release)
Antares Pharma Reports First Quarter 2012 Financial and Operating Results EON: Enhanced Online News (press release) Announced, along with our partner Watson, the launch of Gelnique 3%™ for the treatment of overactive bladder (OAB). Watson will detail Gelnique 3% to physicians with their well-established commercial team focused on urology. Entered into a licensing ... |
Antares Pharma Appoints LeRoux Jooste Senior Vice President Pharmaceutical ... - MarketWatch (press release)
Antares Pharma Appoints LeRoux Jooste Senior Vice President Pharmaceutical ... MarketWatch (press release) In the gel-based area, the Company's FDA approved product is Gelnique 3%(TM) for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for marketing in the US and Canada. |
Antares Pharma to Present at the 15th Annual Bank of America Merrill Lynch ... - MarketWatch (press release)
Antares Pharma to Present at the 15th Annual Bank of America Merrill Lynch ... MarketWatch (press release) In the gel-based area, the Company's FDA approved product is Gelnique 3%(TM) for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for marketing in the US and Canada. Antares Pharma Brings In Record Revenue For Q1 2012 |
Antares Pharma Appoints LeRoux Jooste Senior Vice President Pharmaceutical ... - EON: Enhanced Online News (press release)
Antares Pharma Appoints LeRoux Jooste Senior Vice President Pharmaceutical ... EON: Enhanced Online News (press release) In the gel-based area, the Company's FDA approved product is Gelnique 3%™ for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for marketing in the US and Canada. Antares' portfolio includes Elestrin ... |
Antares Pharma to Host First Quarter 2012 Earnings Call - MarketWatch (press release)
Antares Pharma to Host First Quarter 2012 Earnings Call MarketWatch (press release) In the gel-based area, the Company's FDA approved product is Gelnique 3%(TM) for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for marketing in the US and Canada. |
ANTARES PHARMA INC : 15 May 2012 LeRoux Jooste announcement - 4-traders
ANTARES PHARMA INC : 15 May 2012 LeRoux Jooste announcement 4-traders In the gel-based area, the Company's FDA approved product is Gelnique 3%™ for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for marketing in the US and Canada. Antares' portfolio includes Elestrin® ... |
Antares Pharma to Host First Quarter 2012 Earnings Call - EON: Enhanced Online News (press release)
Antares Pharma to Host First Quarter 2012 Earnings Call EON: Enhanced Online News (press release) In the gel-based area, the Company's FDA approved product is Gelnique 3%™ for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for marketing in the US and Canada. Antares' portfolio includes Elestrin ... |